JP2014517690A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517690A5
JP2014517690A5 JP2014510413A JP2014510413A JP2014517690A5 JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5 JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014510413 A JP2014510413 A JP 2014510413A JP 2014517690 A5 JP2014517690 A5 JP 2014517690A5
Authority
JP
Japan
Prior art keywords
noc
nucleic acid
multimer
igg2ah
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036975 external-priority patent/WO2012154759A2/en
Publication of JP2014517690A publication Critical patent/JP2014517690A/ja
Publication of JP2014517690A5 publication Critical patent/JP2014517690A5/ja
Pending legal-status Critical Current

Links

JP2014510413A 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体 Pending JP2014517690A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09
PCT/US2012/036975 WO2012154759A2 (en) 2011-05-09 2012-05-08 Genetically engineered growth factor variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016204089A Division JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体

Publications (2)

Publication Number Publication Date
JP2014517690A JP2014517690A (ja) 2014-07-24
JP2014517690A5 true JP2014517690A5 (enExample) 2015-06-25

Family

ID=47139949

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Country Status (8)

Country Link
US (3) US20140065113A1 (enExample)
EP (1) EP2707021B1 (enExample)
JP (5) JP2014517690A (enExample)
CN (2) CN103930439A (enExample)
AU (1) AU2012253652B2 (enExample)
CA (1) CA2835453A1 (enExample)
IL (1) IL229316B (enExample)
WO (1) WO2012154759A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126013A2 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
WO2016061396A1 (en) * 2014-10-16 2016-04-21 Counsyl, Inc. Variant caller
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206129T1 (de) * 1989-10-18 2001-10-15 Us Health Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU782496B2 (en) * 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
EP1334127A1 (en) * 2000-11-02 2003-08-13 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2441986A1 (en) * 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
EP1553963A4 (en) * 2002-09-24 2006-05-03 Burnham Inst NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CN101652469B (zh) * 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
EP4043552A1 (en) * 2009-06-11 2022-08-17 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
WO2012126013A2 (en) * 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Similar Documents

Publication Publication Date Title
JP2014517690A5 (enExample)
US20240279303A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
JP6965311B2 (ja) 二重特異的融合タンパク質
JP2017061471A5 (enExample)
CN102781960B (zh) Hsa相关组合物及使用方法
JP2013541335A5 (enExample)
WO2010105573A1 (zh) 抗血管新生融合蛋白
US20240294590A1 (en) Nucleic acid encoding genetically engineered growth factor variants
JP2022002528A (ja) 組織修復のための二重特異性治療用タンパク質
JP2011525363A5 (enExample)
JP2017529059A5 (enExample)
WO2014178078A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
JP7794421B2 (ja) 腫瘍を標的にする合成アデノウイルスおよびその使用
JP2014510519A5 (enExample)
JP2006502702A5 (enExample)
EP2758072A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
JP2025137512A (ja) 新規に設計された共局在化依存性タンパク質スイッチを使用する超特異的細胞標的化
CN105399832A (zh) 一种无标签单链型人源双特异性抗体及其用途
CA3238005A1 (en) Chimeric antigen receptors
CN103342744B (zh) 一种血管新生蛋白及其应用
CN107298714A (zh) 一种双靶标融合蛋白及其制备方法和用途
SE0901565A1 (sv) Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013545440A (ja) マカカ・ファシキュラリス（Ｍａｃａｃａｆａｓｃｉｃｕｌａｒｉｓ）ＣＣＬ１７
CN112480262B (zh) 一种融合蛋白及其制备与应用